AI Article Synopsis

  • A study in southwest Ethiopia evaluated heart failure treatment outcomes, revealing a high in-hospital mortality rate (14.9%), primarily among older patients and those with previous hospitalizations or medication-related issues.
  • Of the 205 patients assessed, 85.1% showed improvement by discharge, indicating that effective management can lead to better outcomes despite the high mortality risk.
  • Key factors linked to higher mortality included being aged 65 or older, previous hospital stays, and having drug therapy problems, suggesting the need for enhanced care and clinical pharmacy services for these patients.

Article Abstract

Background: Heart failure is a significant worldwide health problem that leads to mortality. Therefore, this study aimed to evaluate treatment outcomes and associated factors of heart failure patients who were admitted to hospitals in the southwest of Ethiopia.

Methods And Participants: A multicenter prospective observational study was conducted from 1 February to 1 August 2021. Drug therapy problems were assessed as per the Cipolle, Strands, and Morley drug therapy problems classification method. The drug therapy was registered by using the drug-related problem registration format. The results of logistic regression analysis was interpreted as crude odds ratio and adjusted odds ratio (AOR) at 95% confidence interval (CI) to determine the association between dependent and independent variables.

Results: In our study settings, a total of 205 (85.1%) heart failure patients showed improvement and 36 (14.9%) died at hospital discharge. Being ≥65 years (AOR = 7.14, 95% CI: 2.04-.25.01,  = 0.002), a previous hospitalization (AOR = 6.20, 95% CI: 1.81-21.21,  = 0.004), and the presence of medication-related problems (AOR = 3.65, 95% CI: 1.13-11.73,  = 0.03) were the predictors of mortality.

Conclusion: The prevalence of in-hospital mortality among heart failure patients was found to be high. Previous hospitalization, older age, and the presence of drug therapy problems were the predictors of mortality among heart failure patients. Therefore, proper attention should be given to the management of elderly and re-admitted heart failure patients in addition to their regular care. In addition, hospitals should implement clinical pharmacy services to address any drug-related problems.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11617576PMC
http://dx.doi.org/10.3389/fcvm.2024.1429513DOI Listing

Publication Analysis

Top Keywords

heart failure
28
failure patients
24
drug therapy
16
mortality heart
12
therapy problems
12
multicenter prospective
8
prospective observational
8
observational study
8
odds ratio
8
previous hospitalization
8

Similar Publications

Pulmonary arterial hypertension (PAH) is a syndrome characterized by increased pulmonary vascular resistance and elevated pulmonary artery pressure, ultimately leading to right heart failure and even death. Increasing evidence implicates the fat mass and obesity-associated protein (FTO) in various metabolic and inflammatory pathways; however, its role in pulmonary endothelial function and PAH remains largely unexplored. In this study, we examined the effects of endothelial cell-specific FTO knockout on PAH development.

View Article and Find Full Text PDF

Objectives: There are no studies examining the prevalence of social frailty and associated factors in low- and middle-income countries. This study aimed to assess the prevalence of social frailty and identify the contributing factors among older adults in Türkiye.

Methods: This cross-sectional study included 570 participants aged 65 and older, all outpatients at a geriatric clinic.

View Article and Find Full Text PDF

Background: Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract infection, hospitalisation and death in adults.

Methods: Based on evidence regarding the impact of RSV on adult populations at risk for severe infection and the efficacy and safety of RSV vaccines, the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine endorses this position paper with recommendations to prevent RSV-associated disease and its complications in adults through vaccination.

Conclusion: The RSV vaccine is recommended for people aged ≥50 years with risk factors (chronic obstructive pulmonary disease, asthma, heart failure, coronary artery disease, diabetes, chronic kidney disease, chronic liver disease, immunocompromise, frailty, dementia, and residence in a nursing home) and all persons aged ≥60 years.

View Article and Find Full Text PDF

This case report highlights a potential vaccine safety concern associated with the Pseudorabies virus (PRV) live vaccine, which warrants further investigation for comprehensive understanding. Vaccine-induced immune thrombotic thrombocytopenia (VITT), a novel syndrome of adverse events following adenovirus vector COVID-19 vaccines, was observed after vaccination with Zoetis PR-VAC PLUS. This led to a 100% morbidity and high mortality among PRV-free Danish purebred pigs from Danish Genetics Co.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!